Amarin Corp Plc (AMRN)

[KCSVEN]

In the article even AF says no competitor for Vascepa as will be limited to a small subset of patients so AF does indeed nail it: no real risk to AMRN and Vascepa.

"ISIS-APOCIIIRx is a potential competitor to Amarin's Vascepa, BUT the need for weekly injections plus the risk that long-term use may lead to safety issues are likely to limit it to use in patients with much more severe disease"